Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.59 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8823384 | 1.00 | SRD5A2 (0.59) | SRD5A2SRD5A1AR | |
| SCHEMBL14355642 | 0.82 | SRD5A2 (0.69) | SRD5A2SRD5A1AR | |
| SCHEMBL13970806 | 0.82 | SRD5A2 (0.69) | SRD5A2SRD5A1AR | |
| SCHEMBL13950495 | 0.82 | SRD5A2 (0.69) | SRD5A2SRD5A1AR | |
| SCHEMBL5906987 | 0.82 | SRD5A2 (0.69) | SRD5A2SRD5A1AR | |
| SCHEMBL5273346 | 0.82 | SRD5A2 (0.69) | SRD5A2SRD5A1AR | |
| SCHEMBL5273343 | 0.82 | SRD5A2 (0.69) | SRD5A2SRD5A1AR | |
| SCHEMBL14477870 | 0.82 | SRD5A2 (0.69) | SRD5A2SRD5A1AR | |
| SCHEMBL8823369 | 0.82 | SRD5A1 (0.61) | SRD5A2SRD5A1 | |
| SCHEMBL8823378 | 0.80 | SRD5A2 (0.58) | SRD5A2SRD5A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0538192-B1 | New 17-beta-substituted aza-androstanderivatives | CIBA GEIGY AG (CH) | 1997-04-23 | — | — | EP | disclosed |
| US-5304562-A | Inhibitors of 5-alpha-reductase; treating prostate disorders | CIBA-GEIGY CORPORATION (US) | 1994-04-19 | — | — | US | disclosed |
| EP-0538192-A1 | New 17-beta-substituted aza-androstanderivatives | CIBA-GEIGY AG (CH) | 1993-04-21 | — | — | EP | disclosed |